Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo de TP-3654 oral em pacientes com mielofibrose

30 de setembro de 2026 atualizado por: Sumitomo Pharma America, Inc.

Um estudo de Fase 1/2, aberto, escalonamento de dose, segurança, farmacocinética e farmacodinâmica do TP-3654 oral em pacientes com mielofibrose primária ou secundária de risco intermediário ou alto

This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.

Visão geral do estudo

Descrição detalhada

Arm 1 will enroll patients who have been previously treated and failed on a JAK inhibitor or ineligible to receive treatment with a JAK inhibitor.

Arm 2 will enroll patients who are on a stable dose of ruxolitinib, but who have either lost response or had a suboptimal or plateau in response.

Arm 3 will enroll patients who have been previously treated with a JAK inhibitor (except momelotinib)

Tipo de estudo

Intervencional

Inscrição (Estimado)

240

Estágio

  • Fase 2
  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

      • Halle, Alemanha
        • Recrutamento
        • Universitätsmedizin Halle
        • Contato:
          • SMPA Investigative Site
      • Lübeck, Alemanha
        • Recrutamento
        • Universitätsklinikum Schleswig-Holstein
        • Contato:
          • SMPA Investigative Site
      • Adelaide, Austrália
        • Recrutamento
        • Icon Cancer Centre (Ashford Cancer Centre Research)
        • Contato:
    • South Australia
      • Adelaide, South Australia, Austrália
    • Victoria
      • Box Hill, Victoria, Austrália
        • Recrutamento
        • Eastern Health Box Hill Hospital
        • Contato:
          • SMPA Investigative Site
      • Clayton, Victoria, Austrália
        • Recrutamento
        • Monash University
        • Contato:
          • SMPA Investigative Site
      • Fitzroy, Victoria, Austrália
        • Recrutamento
        • St Vincent's Hospital Melbourne
        • Contato:
          • SMPA Investigative Site
      • Melbourne, Victoria, Austrália
        • Recrutamento
        • Peter McCallum Center
        • Contato:
          • SMPA Investigative Site
      • Richmond, Victoria, Austrália
        • Recrutamento
        • Epworth Healthcare
        • Contato:
          • SMPA Investigative Site
      • Antwerp, Bélgica, 2020
        • Recrutamento
        • ZNA Cadix
        • Contato:
          • SMPA Investigative Site
      • Antwerp, Bélgica, 2030
        • Recrutamento
        • ZNA Middelheim
        • Contato:
          • SMPA Investigative Site
      • Ghent, Bélgica, 9000
        • Recrutamento
        • Universitair Ziekenhuis Gent
        • Contato:
          • SMPA Investigative Site
      • Liège, Bélgica, 4000
        • Recrutamento
        • CHU de Liege
        • Contato:
          • SMPA Investigative Site
    • Vlaams-Brabant
      • Leuven, Vlaams-Brabant, Bélgica, 3000
        • Recrutamento
        • University Hospitals Leuven
        • Contato:
          • SMPA Investigative Site
    • Alberta
    • British Columbia
      • Vancouver, British Columbia, Canadá, V6T 1Z3
        • Recrutamento
        • University of British Columbia
        • Contato:
          • SMPA Investigative Site
      • Vancouver, British Columbia, Canadá, V6T 1Z3
        • Recrutamento
        • St. Paul's Hospital Hematology/Oncology Research
        • Contato:
    • Ontario
      • Hamilton, Ontario, Canadá, L8V 5C2
        • Recrutamento
        • Juravinski Cancer Center
        • Contato:
          • SMPA Investigative Site
      • Toronto, Ontario, Canadá, M5G 2M9
        • Recrutamento
        • Princess Margaret Cancer Center
        • Contato:
    • Quebec
      • Montreal, Quebec, Canadá, H3T 1E2
        • Recrutamento
        • Jewish General Hospital
        • Contato:
          • SMPA Investigative Site
      • Barcelona, Espanha
        • Recrutamento
        • Hospital Universitario y Politecnico La Fe
        • Contato:
          • SMPA Investigative Site
      • Barcelona, Espanha
        • Recrutamento
        • Institut Catala d'Oncologia
        • Contato:
          • SMPA Investigative Site
      • Salamanca, Espanha
        • Recrutamento
        • Hospital Universitario de Salamanca
        • Contato:
          • SMPA Investigative Site
    • Alabama
      • Birmingham, Alabama, Estados Unidos, 35294
        • Recrutamento
        • University of Alabama
        • Contato:
          • Tiffany Hill
          • Número de telefone: 205-934-9591
    • Arizona
      • Tucson, Arizona, Estados Unidos, 85724
        • Recrutamento
        • The University of Arizona Cancer Center
        • Contato:
    • California
      • Duarte, California, Estados Unidos, 91010
        • Recrutamento
        • City of Hope
        • Contato:
      • Los Angeles, California, Estados Unidos, 90033
        • Recrutamento
        • University of Southern California
        • Contato:
      • Newport Beach, California, Estados Unidos, 92663
        • Recrutamento
        • Hoag Family Cancer Institute
        • Contato:
    • Colorado
    • Connecticut
      • New Haven, Connecticut, Estados Unidos, 06510
        • Recrutamento
        • Yale School of Medicine
        • Contato:
    • Florida
      • Gainesville, Florida, Estados Unidos, 32608
        • Concluído
        • University of Florida Health Shands Cancer Hospital
      • Miami, Florida, Estados Unidos, 33136
        • Recrutamento
        • University of Miami
        • Contato:
      • Miami, Florida, Estados Unidos, 33176
        • Recrutamento
        • Baptist Health - Miami Cancer Institute
        • Contato:
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30322
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60637
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21201
        • Recrutamento
        • University of Maryland
        • Contato:
          • Maria Baer, MD
          • Número de telefone: 410-328-8708
          • E-mail: mbaer@umm.edu
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02114
        • Recrutamento
        • Massachusetts General Hospital
        • Contato:
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48109
        • Recrutamento
        • University of Michigan
        • Contato:
    • Minnesota
      • Minneapolis, Minnesota, Estados Unidos, 55455
        • Recrutamento
        • University of Minnesota
        • Contato:
    • Missouri
      • St Louis, Missouri, Estados Unidos, 63110
        • Recrutamento
        • Washington University of Medicine
        • Contato:
    • New Jersey
      • Hackensack, New Jersey, Estados Unidos, 07601
        • Recrutamento
        • John Theurer Cancer Center at Hackensack University Medical Center
        • Contato:
    • New York
      • Buffalo, New York, Estados Unidos, 14263
        • Concluído
        • Roswell Park Comprehensive Cancer Center
      • New York, New York, Estados Unidos, 10065
        • Recrutamento
        • Memorial Sloan Kettering Cancer Center
        • Contato:
      • New York, New York, Estados Unidos, 10029
      • New York, New York, Estados Unidos, 10065
        • Recrutamento
        • Weill Cornell Medical Center
        • Contato:
      • The Bronx, New York, Estados Unidos, 10461
    • North Carolina
      • Durham, North Carolina, Estados Unidos, 27710
    • Ohio
      • Columbus, Ohio, Estados Unidos, 43210
    • South Carolina
      • Charleston, South Carolina, Estados Unidos, 29425
        • Recrutamento
        • Medical University of South Carolina
        • Contato:
    • Tennessee
      • Nashville, Tennessee, Estados Unidos, 37232
        • Recrutamento
        • Vanderbilt University
        • Contato:
          • SMPA Investigative Site
      • Nashville, Tennessee, Estados Unidos, 37203
    • Texas
      • Houston, Texas, Estados Unidos, 77054
        • Recrutamento
        • MD Anderson Cancer Center
        • Contato:
    • Utah
      • Salt Lake City, Utah, Estados Unidos, 84112
        • Recrutamento
        • Huntsman Cancer Institute
        • Contato:
    • Virginia
      • Charlottesville, Virginia, Estados Unidos, 22903
        • Recrutamento
        • University of Virginia Cancer Center
        • Contato:
    • Washington
      • Seattle, Washington, Estados Unidos, 98109
        • Recrutamento
        • University of Washington - Fred Hutchinson Cancer Center
        • Contato:
      • Amiens, França, 80054
        • Recrutamento
        • Centre Hospitalier Universitaire D'Amiens
        • Contato:
          • SMPA Investigative Site
      • Angers, França, 9000
        • Recrutamento
        • CHU Angers
        • Contato:
          • SMPA Investigative Site
      • Lyon, França, 69495
        • Recrutamento
        • Centre Hospitalier Lyon Sud
        • Contato:
          • SMPA Investigative Site
      • Nice, França, 06200
        • Recrutamento
        • Hospitalier Universitaire (CHU) de Nice - Hopital de l'Archet
        • Contato:
          • SMPA Investigative Site
      • Nîmes, França, 30029
        • Recrutamento
        • Institut de cancerologie du Gard
        • Contato:
          • SMPA Investigative Site
      • Nîmes, França
        • Recrutamento
        • Institut de cancerologie du Gard
        • Contato:
          • SMPA Investigative Site
      • Paris, França, 75010
        • Recrutamento
        • Hospital Saint Louis
        • Contato:
          • SMPA Investigative Site
      • Poitiers, França, 86021
        • Recrutamento
        • University Hospital of Poitiers
        • Contato:
          • SMPA Investigative Site
      • Villejuif, França, 94805
        • Recrutamento
        • Institut Gustave Roussy
        • Contato:
          • SMPA Investigative Site
      • Alessandria, Itália, 15121
        • Recrutamento
        • Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo
        • Contato:
          • SMPA Investigative Site
      • Aviano, Itália, 33081
        • Recrutamento
        • Istituto Nazionale Tumori, IRCCS Centro di Riferimento Oncologico di Aviano
      • Bologna, Itália, 40138
        • Recrutamento
        • IRCCS Azienda Ospedaliero -Universitaria Di Bologna - Dipartimento Malattie Oncologiche ed Ematologiche - UO Ematologia
        • Contato:
          • SMPA Investigative Site
      • Brescia, Itália
        • Recrutamento
        • ASST - Spedali Civili di Brescia
        • Contato:
          • SMPA Investigative Site
      • Meldola, Itália, 47014
        • Recrutamento
        • IRCCS istituto Romagnolo per lo studio dei tumori "Dino Amadori"
        • Contato:
          • SMPA Investigative Site
      • Milan, Itália, 20122
        • Recrutamento
        • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
        • Contato:
          • SMPA Investigative Site
      • Torino, Itália, 10126
        • Recrutamento
        • Azienda Ospedaliera Universitaria Citta' Della Salute E della Scienza di Torino
        • Contato:
          • SMPA Investigative Site
      • Aichi, Japão
      • Aomori, Japão
        • Recrutamento
        • Aomori Prefectural Central Hospital
        • Contato:
      • Chiba, Japão
        • Recrutamento
        • National Cancer Center Hospital East
        • Contato:
      • Fukuoka, Japão
      • Hokkaido, Japão
        • Recrutamento
        • Hokkaido University Hospital
        • Contato:
      • Kamakura, Japão, 247-8533
        • Recrutamento
        • Shonan Kamakura General Hospital
        • Contato:
      • Miyazaki, Japão
        • Recrutamento
        • University of Miyazaki Hospital
        • Contato:
      • Okayama, Japão
        • Recrutamento
        • Okayama University Hospital
        • Contato:
      • Osaka, Japão
        • Recrutamento
        • The University of Osaka Hospital
        • Contato:
          • Michiko Ichii, MD
          • Número de telefone: 06-6879-5111
      • Saitama, Japão
        • Concluído
        • Saitama Medical Center
      • Sendai, Japão
        • Recrutamento
        • Tohoku University Hospital
        • Contato:
          • Noriko Fukuhara, MD
          • Número de telefone: 022-717-7000
      • Shizuoka, Japão
        • Concluído
        • Shizuoka Cancer Center
      • Tokyo, Japão, 160-0023
        • Recrutamento
        • Tokyo Medical University Hospital
        • Contato:
      • Tokyo, Japão
        • Recrutamento
        • Juntendo University Hospital
        • Contato:
      • Tokyo, Japão, 179-0072
        • Recrutamento
        • Nerima Hikarigaoka Hospital
        • Contato:
      • Tsu, Japão
      • Lincoln, Reino Unido
        • Recrutamento
        • Lincoln County Hospital
        • Contato:
          • SMPA Investigative Site
      • Lincoln, Reino Unido
        • Recrutamento
        • United Lincolnshire Hospitals NHS Trust - Pilgrim Hospital
        • Contato:
          • SMPA Investigative Site
      • London, Reino Unido
        • Recrutamento
        • University College London Hospital's NHS foundation Trust
        • Contato:
          • SMPA Investigative Site
      • Oxford, Reino Unido
        • Recrutamento
        • Oxford University Hospitals NHS Foundation
        • Contato:
          • SMPA Investigative Site

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Patients must meet all of the following inclusion criteria to be eligible:

Nuvisertib (TP-3654) Monotherapy Arm:

  • Confirmed pathological diagnosis of primary myelofibrosis (PMF) or post-PV-MF/post-ET- MF and intermediate or high-risk primary or secondary MF
  • Previously treated with JAK inhibitor(s) and is intolerant, resistant, refractory or has lost response to the JAK inhibitor(s) or is ineligible to be treated with JAK inhibitor
  • Fulfill the following clinical laboratory parameters:
  • Platelet count ≥ 25 x 10^9 /L, without assistance of growth factors or platelet transfusions
  • ANC ≥ 1 x 10^9/L without assistance of granulocyte growth factors
  • Peripheral blood blast count < 5%
  • ECOG performance status ≤ 1
  • Life expectancy ≥ 6 months
  • Adequate renal function
  • Adequate hepatic function
  • Adequate coagulation function
  • Splenomegaly (spleen volume of ≥ 450 cm3 by MRI or CT scan) within 2 weeks prior to Cycle 1 Day 1.
  • Dose escalation: At least 2 symptoms measurable (score ≥ 1) using the MF-SAF
  • Dose expansion: At least 2 symptoms measurable with each score of ≥ 3 or a total average score of ≥ 10 per MFSAF

Nuvisertib (TP-3654) + Ruxolitinib Arm:

  • Confirmed pathological diagnosis of PMF or post-PV-MF/post ET- MF and intermediate or high-risk primary or secondary MF
  • On ruxolitinib treatment for ≥ 6 months, and on a stable dose of ruxolitinib (5 to 25 mg BID) for ≥ 8 weeks prior to the first dose of nuvisertib, but has either lost response or had a suboptimal or plateau in response
  • Fulfills the following clinical laboratory parameters:
  • Platelet count ≥ 50 × 10^9/L (without assistance of growth factors or platelet transfusions)
  • ANC ≥ 1 × 109/L without assistance of granulocyte growth factors
  • Peripheral blood blast count < 5% at screening
  • Adequate renal function
  • Adequate hepatic function
  • Adequate coagulation function
  • Splenomegaly (spleen volume of ≥ 450 cm3 by MRI/CT scan) within 2 weeks prior to Cycle 1 Day 1
  • At least 2 symptoms measurable with each score ≥ 3 or a total average score of ≥ 10 per MFSAF v4.0
  • ECOG performance status ≤ 1
  • Life expectancy ≥ 6 months

Nuvisertib (TP-3654) + Momelotinib Arm

  • Confirmed pathological diagnosis of PMF or post-PV-MF/post ET-MF and intermediate or high-risk primary or secondary MF
  • Previously treated with an approved JAK inhibitor (except momelotinib) for PMF or Post-PV/ET MF for ≥ 12 weeks, or ≥ 4 weeks if JAK inhibitor therapy was complicated by a transfusion requirement of ≥ 4 units of red blood cells in 8 weeks, or Grade 3/4 AEs of thrombocytopenia, anemia, or hematoma
  • Fulfills the following clinical laboratory parameters:
  • Anemic, defined as Hb <10 g/dL or requiring RBC transfusion at baseline
  • Platelet count ≥ 50 × 109/L (without assistance of growth factors or platelet transfusions)
  • ANC ≥ 1 × 109/L without assistance of granulocyte growth factors
  • Peripheral blood blast count < 5% at screening
  • Adequate renal function
  • Adequate hepatic function
  • Adequate coagulation function
  • Splenomegaly (spleen volume of ≥ 450 cm3 by MRI/CT scan) within 2 weeks prior to Cycle 1 Day 1
  • At least 2 symptoms measurable with each score of ≥ 3 or a total average score of ≥ 10 per MFSAF v4.0
  • ECOG performance status ≤ 1
  • Life expectancy ≥ 6 months

Patients meeting any one of these exclusion criteria will be prohibited from participating in this study:

Nuvisertib (TP-3654) Monotherapy Arm:

  • Received previous systemic antineoplastic therapy or any experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1. Hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
  • Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or not recovered adequately from from surgery prior to first dose.
  • Splenic irradiation within 6 months prior to Screening or prior splenectomy.
  • Prior allogeneic stem cell transplant within the last 6 months.
  • Eligible for allogeneic bone marrow or stem cell transplantation.
  • Unresolved Grade ≥ 2 non-hematological toxicity related to prior treatment
  • History of symptomatic congestive heart failure, or myocardial infarction, or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; left ventricular ejection fraction (LVEF) < 45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1.
  • Corrected QT interval > 480msec.
  • Prior or concurrent malignancy that could interfere with the investigational regime.
  • Known history of chronic liver disease, e.g. portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc.
  • Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic antimicrobial within 1 week prior to Cycle 1 Day 1.
  • Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
  • Exhibited allergic reactions or sensitivity to nuvisertib, or similar compound.
  • Medical condition or GI tract surgery that could impair absorption or result in short bowel syndrome with diarrhea.
  • Systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to the first dose of study treatment (note: topical, inhaled, nasal, and ophthalmic steroids are not prohibited).
  • Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding.
  • Pregnant or breastfeeding
  • Currently receiving any other investigational agent.

Nuvisertib (TP-3654) + Ruxolitinib Arm:

  • Received previous systemic antineoplastic therapy (other than ruxolitinib) or any other experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1 (Note: Prior treatment with nuvisertib is not allowed. Hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
  • Received systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to Cycle 1 Day 1 (Note: Topical, inhaled, nasal, and ophthalmic steroids are not prohibited)
  • Known allergic reactions or sensitivity to nuvisertib, or similar compound.
  • Splenic irradiation within 6 months prior to Screening or prior splenectomy
  • Prior allogeneic stem cell transplant within the last 6 months (Note: Patients who have relapsed after 6 months post-transplant and do not have active GVHD are eligible).
  • Eligible for allogeneic bone marrow or stem cell transplantation (Note: Patients who are not willing to undergo transplantation or for whom a suitable donor is not available are considered as transplant ineligible.)
  • Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or have not recovered adequately prior to first dose.
  • Active, uncontrolled bacterial, viral, or fungal infections, requiring parenteral antimicrobial within 1 week prior to Cycle 1 Day 1
  • Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
  • Known history of chronic liver disease (eg, portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc) (Note: Abnormal liver morphology at baseline imaging may require additional testing, as needed).
  • Unresolved Grade ≥ 2 non-hematological adverse events related to prior treatment (stable Grade 2 conditions may be permitted in consultation with the Sponsor)
  • History of myocardial infarction or symptomatic congestive heart failure or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; LVEF <45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1
  • Corrected QTcF of > 480 msec
  • Prior or concurrent malignancy that could interfere with the safety or efficacy assessment of the study intervention
  • History of a medical condition or GI tract surgery that could impair absorption or could result in short bowel syndrome with diarrhea
  • Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding
  • Pregnant or breastfeeding

Nuvisertib (TP-3654) + Momelotinib Arm:

  • Received previous systemic antineoplastic therapy or any experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1 (Notes: Prior treatment with momelotinib or nuvisertib is not allowed; in patients with ongoing JAK inhibitor therapy, ie, ruxolitinib, at screening, JAK inhibitor therapy must be tapered over a period of at least 1 week. Patients on a low dose of ruxolitinib (eg, 5 mg QD) may have a reduced taper period or no taper; hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
  • Received systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to Cycle 1 Day 1 (Note: Topical, inhaled, nasal, and ophthalmic steroids are not prohibited).
  • Known allergic reactions or sensitivity to nuvisertib, momelotinib, or any structurally similar drug, or to any component of the formulations of either study intervention
  • Splenic irradiation within 6 months prior to screening or prior splenectomy
  • Prior allogenic stem cell transplant within the last 6 months (Note: Patients who have relapsed after 6 months post-transplant and do not have active GVHD are eligible).
  • Eligible for allogeneic bone marrow or stem cell transplantation (Note: Patients who are not willing to undergo transplantation or for whom a suitable donor is not available are considered as transplant ineligible).
  • Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or have not recovered adequately from surgery prior to first dose.
  • Active, uncontrolled bacterial, viral, or fungal infections, requiring parenteral antimicrobial within 1 week prior to Cycle 1 Day 1
  • Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
  • Known history of chronic liver disease (eg, portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc) (Note: Abnormal liver morphology at baseline imaging may require additional testing, as needed)
  • Unresolved Grade ≥ 2 non-hematological adverse events related to prior treatment (stable Grade 2 conditions may be permitted in consultation with the Sponsor)
  • Presence of Grade ≥ 2 peripheral neuropathy
  • History of myocardial infarction or symptomatic congestive heart failure or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; LVEF < 45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1
  • Corrected QTcF of > 480 msec
  • Prior or concurrent malignancy that could interfere with the safety or efficacy assessment of the study intervention
  • History of a medical condition or GI tract surgery that could impair absorption or could result in short bowel syndrome with diarrhea
  • Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding
  • Pregnant or breastfeeding

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Não randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Braço 1: nuvisertib (TP-3654)

Oral PIM Inhibitor

Outros nomes:
  • TP-3654
Experimental: Braço 2: nuvisertibe (TP-3654) adicionado ao ruxolitinibe

Oral PIM Inhibitor

Outros nomes:
  • TP-3654

Oral JAK inhibitor

Outros nomes:
  • Jakafi
Experimental: Braço 3: nuvisertibe (TP-3654) em combinação com momelotinibe

Oral PIM Inhibitor

Outros nomes:
  • TP-3654

Oral JAK inhibitor

Outros nomes:
  • Ojjaara

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Determine the incidence of dose-limiting toxicities (DLTs)
Prazo: 28 days

Number of participants with DLTs

28 days
Determine the incidence of treatment emergent adverse events
Prazo: From start of treatment to end of study

Number of participants with Treatment Emergent Adverse Events and Serious Adverse Events

From start of treatment to end of study
Assess patients for any evidence of preliminary activity by determining the number of patients with ≥ 35% spleen volume reduction (SVR35)
Prazo: From start of treatment to end of study

Number of participants with ≥ 35% spleen volume reduction (SVR35)

From start of treatment to end of study

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Number of participants achieving objective response by IWG-MRT response criteria
Prazo: From start of treatment to end of study

Number of participants achieving complete remission, partial remission, clinical improvement, progressive disease and stable disease.

From start of treatment to end of study
Number of participants who have ≥ 25% spleen volume reduction
Prazo: Every 12 weeks from cycle 1 day 1 through cycle 19 day 1, and then every 24 weeks therafter during treatment.

Number of participants who have ≥ 25% spleen volume reduction compared to baseline

Every 12 weeks from cycle 1 day 1 through cycle 19 day 1, and then every 24 weeks therafter during treatment.
Number of participants with ≥ 50% improvement in total symptom score (TSS50) at week 24
Prazo: 24 weeks

Number of participants who have ≥ 50% total symptom score reduction by MFSAF compared to baseline after 24 weeks of treatment.

24 weeks
Determine the change in Patient Global Impression of Change (PGIC) at week 24 through end of study.
Prazo: After 24 weeks of treatment to end of study

Change in PGIC score

After 24 weeks of treatment to end of study
Determine the incidence of QT interval changes
Prazo: 25 hours

Changes in QT interval and heart rhythm

25 hours
Establish the half-life (t½) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Prazo: 24 hours

The estimate of time for the nuvisertib concentration or amount to be reduced by half

24 hours
Establish the Area under the plasma concentration versus time curve (AUC) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Prazo: 24 hours

The amount of drug exposure over 24 hours period after administration

24 hours
Establish the Peak Plasma Concentration (Cmax) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Prazo: 24 hours

The maximum nuvisertib concentration after administration

24 hours
Establish the Time of Maximum concentration observed (tmax) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Prazo: 24 hours

The time to reach maximum nuvisertib concentration

24 hours

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Número de pacientes com redução da fibrose da medula óssea
Prazo: A cada 24 semanas até o final do estudo
A cada 24 semanas até o final do estudo
Braços combinados de Nuvisertib: Avaliar o aumento da hemoglobina ≥1,5 ou ≥ 2 g/dL em relação ao valor basal
Prazo: Do início do tratamento ao final do estudo
Do início do tratamento ao final do estudo
Braços combinados de Nuvisertib: Avaliar o estado de independência da transfusão de glóbulos vermelhos ou qualquer alteração de requisitos
Prazo: Do início do tratamento ao final do estudo
Do início do tratamento ao final do estudo
Monoterapia com NuVisertib: Alterações na contagem de plaquetas ao longo do tempo em pacientes com contagem inicial de plaquetas <100 x 10^9/L
Prazo: Desde o início do tratamento até o fim do estudo
Desde o início do tratamento até o fim do estudo
Study potential pharmacodynamic (PD) markers of nuvisertib
Prazo: 12 months

Evaluate exploratory biomarkers, including change in protein phosphorylation and inflammatory cytokines, in peripheral blood samples and bone marrow biopsy samples.

12 months
Establish overall survival
Prazo: From start of treatment to end of study

The time interval from treatment start date to date of death from any cause

From start of treatment to end of study

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

16 de dezembro de 2019

Conclusão Primária (Estimado)

30 de abril de 2027

Conclusão do estudo (Estimado)

30 de abril de 2030

Datas de inscrição no estudo

Enviado pela primeira vez

8 de novembro de 2019

Enviado pela primeira vez que atendeu aos critérios de CQ

22 de novembro de 2019

Primeira postagem (Real)

25 de novembro de 2019

Atualizações de registro de estudo

Última Atualização Postada (Real)

2 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

30 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever